HELPING ONCOLOGISTS ADAPT TO THE PRECISION AGE OF CANCER CARE
Cancer patients like Suzanne expect their physician to know precisely the best treatment path.
PATIENT PROFILE: Suzanne, 58-year-old female | aNSCLC, Stage 3
Trapelo knows this isn’t always possible.
The rapid growth and complexity of precision medicine is changing too quickly for many physicians (and payers) to keep up.
Oncologists must factor in thousands of data points, complex genomic testing panels, ever-changing clinical information, and myriad insurance and reimbursement policies—all while making life and death decisions.
Because of this complexity, not all patients are being tested according to guidelines
Recent data shows that only 7% of aNSCLC patients treated in the community setting were appropriately tested for the seven biomarkers that are proven to inform the latest targeted treatment options and clinical trials. Source
† All 4 includes EGFR, ALK, ROS1, BRA. ‡ All 7 includes EGFR, ALK, ROS1, BRAF, RET, MET, ERBB2.
Reference: Gierman HJ, Goldfarb S, Labrador M, et al. Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. J Clin Oncol. 2019;37(suppl; abstr 1585).
When physicians use Trapelo, they consistently test guideline markers.
Trapelo improves biomarker selection and testing ~ 94.4%
Reference: Gierman HJ, Goldfarb S, Labrador M, et al. Genomic testing and treatment landscape in patients with advanced non-small cell lung cancer (aNSCLC) using real-world data from community oncology practices. J Clin Oncol. 2019;37(suppl; abstr 1585).
“As the field of precision medicine grows and the data continues to expand… it's important for clinicians and payers to have access to this data when it really matters, and that's when they're making a treatment decision or a coverage decision.”
– Janine Morales, PhD, Pharmacology, Precision Medicine Podcast Guest
Trapelo takes the complexity out of cancer care by giving Suzanne’s doctor access to the latest, evidence-based testing and treatments for NSCLC.
Suzanne's doctor and insurer can collaborate in real time to quickly align on the best treatment options, reducing her risk of adverse events, eliminating delays and helping her manage out-of-pocket costs – just as she expected.
Trapelo knows:
-
if testing is appropriate and which biomarkers should be tested;
-
which tests to order, and which labs are preferred
-
most appropriate treatment options including clinical trials; and
-
which test/treatments may have streamlined prior authorization.
TRAPELO IN PRACTICE TODAY:
-
one portal, many labs (lab agnostic)
-
reduces test order process from 20 to less than 5 minutes
-
currently implemented at 75+ locations
-
over 1,000 users
How does Trapelo work?
Take an inside look in this brief 5-minute demo
